Document is current
Any future updates will be listed below
-
Authors
Liu, Yiyang
Ramos, Stephen D
Hanna, David B
Jones, Deborah L
Lazar, Jason M
Kizer, Jorge R
Cohen, Mardge H
Haberlen, Sabina A
Adimora, Adaora A
Lahiri, Cecile D
Wise, Jenni M
Friedman, Mackey R
Plankey, Michael
Chichetto, Natalie E https://orcid.org/0000-0003-1543-1754
-
Funding
Funding for this research was provided by:
National Institute on Alcohol Abuse and Alcoholism (K01AA029042)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (K23AI124913, R01AI145552)
NHLBI Division of Intramural Research (K01HL137557, K12HL143958, U01-HL146203, U01HL146194)
National Institute on Minority Health and Health Disparities (R01MD010680)
National Institute on Drug Abuse (T32DA023356)
- License Information
-
More Information
Article History
Accepted: 26 June 2023
First Online: 7 July 2023
Statements and Declarations
:
: Dr. Liu receives grant funding from Merck. Dr. Kizer reports stock ownership in Abbott, Bristol Myers Squibb, Johnson & Johnson, Medtronic, Merck, and Pfizer. Dr. Lahiri receives grant funding from Merck and serves on the Advisory Board for Theratechnologies, Inc. Dr. Adimora has received fees for consulting from Merck and Gilead. Merck and Gilead have provided her institution with funding for her research. None of the other authors had any financial or other conflicts of interest.
: The primary MACS study was approved by the institutional review boards (IRB) of each study center (John Hopkins, Northwestern University, University of California Los Angeles, and University of Pittsburgh). Written informed consent was provided by participants. The University of Florida IRB approved the described secondary analyses of MACS data.
: Not applicable.
